CN116836299B - Chimeric antigen receptor and uses thereof - Google Patents
Chimeric antigen receptor and uses thereof Download PDFInfo
- Publication number
- CN116836299B CN116836299B CN202310687031.8A CN202310687031A CN116836299B CN 116836299 B CN116836299 B CN 116836299B CN 202310687031 A CN202310687031 A CN 202310687031A CN 116836299 B CN116836299 B CN 116836299B
- Authority
- CN
- China
- Prior art keywords
- cells
- nucleic acid
- acid molecule
- fragment
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 70
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 100
- 210000002865 immune cell Anatomy 0.000 claims abstract description 93
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims abstract description 53
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims abstract description 52
- 239000012634 fragment Substances 0.000 claims abstract description 42
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims abstract description 13
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims description 206
- 108020004707 nucleic acids Proteins 0.000 claims description 84
- 102000039446 nucleic acids Human genes 0.000 claims description 84
- 150000007523 nucleic acids Chemical class 0.000 claims description 84
- 210000000822 natural killer cell Anatomy 0.000 claims description 48
- 239000013604 expression vector Substances 0.000 claims description 36
- 230000009261 transgenic effect Effects 0.000 claims description 36
- 239000013598 vector Substances 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 239000002773 nucleotide Substances 0.000 claims description 18
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- 241000700605 Viruses Species 0.000 claims description 15
- 210000005259 peripheral blood Anatomy 0.000 claims description 12
- 239000011886 peripheral blood Substances 0.000 claims description 12
- 206010033128 Ovarian cancer Diseases 0.000 claims description 11
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 11
- 201000007270 liver cancer Diseases 0.000 claims description 11
- 208000014018 liver neoplasm Diseases 0.000 claims description 11
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 9
- 108020001507 fusion proteins Proteins 0.000 claims description 9
- 102000037865 fusion proteins Human genes 0.000 claims description 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 9
- 201000002528 pancreatic cancer Diseases 0.000 claims description 9
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 9
- 239000013603 viral vector Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 230000003834 intracellular effect Effects 0.000 claims description 7
- 230000004068 intracellular signaling Effects 0.000 claims description 7
- 230000001717 pathogenic effect Effects 0.000 claims description 6
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 210000004700 fetal blood Anatomy 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 239000003446 ligand Substances 0.000 abstract description 37
- 238000011282 treatment Methods 0.000 abstract description 29
- 230000031146 intracellular signal transduction Effects 0.000 abstract description 7
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 38
- 102000003812 Interleukin-15 Human genes 0.000 description 35
- 230000002147 killing effect Effects 0.000 description 31
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 31
- 230000014509 gene expression Effects 0.000 description 29
- 108090000765 processed proteins & peptides Proteins 0.000 description 22
- 238000000034 method Methods 0.000 description 21
- 230000000694 effects Effects 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 210000004881 tumor cell Anatomy 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 14
- 230000000259 anti-tumor effect Effects 0.000 description 13
- 238000012239 gene modification Methods 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 108020003285 Isocitrate lyase Proteins 0.000 description 11
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 229910052618 mica group Inorganic materials 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 239000002609 medium Substances 0.000 description 9
- 239000010445 mica Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000010172 mouse model Methods 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 108010075254 C-Peptide Proteins 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 102000001398 Granzyme Human genes 0.000 description 6
- 108060005986 Granzyme Proteins 0.000 description 6
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 6
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000005017 genetic modification Effects 0.000 description 5
- 235000013617 genetically modified food Nutrition 0.000 description 5
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 5
- 229930192851 perforin Natural products 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 241000713666 Lentivirus Species 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000008629 immune suppression Effects 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000005909 tumor killing Effects 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- 101000607320 Homo sapiens UL16-binding protein 2 Proteins 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- 102100039989 UL16-binding protein 2 Human genes 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 201000005787 hematologic cancer Diseases 0.000 description 3
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 210000005008 immunosuppressive cell Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 230000009437 off-target effect Effects 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 102000010970 Connexin Human genes 0.000 description 2
- 108050001175 Connexin Proteins 0.000 description 2
- 206010050685 Cytokine storm Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 108010040476 FITC-annexin A5 Proteins 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 102000004556 Interleukin-15 Receptors Human genes 0.000 description 2
- 108010017535 Interleukin-15 Receptors Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 108091008877 NK cell receptors Proteins 0.000 description 2
- 102000010648 Natural Killer Cell Receptors Human genes 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 102000052575 Proto-Oncogene Human genes 0.000 description 2
- 108700020978 Proto-Oncogene Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 101150058049 car gene Proteins 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 206010052015 cytokine release syndrome Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000003976 gap junction Anatomy 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108050005848 Annexin A10 Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- -1 IL-2 Proteins 0.000 description 1
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 229930191564 Monensin Natural products 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 101100182935 Penicillium citrinum MSDC gene Proteins 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- 101100377577 Picea glauca 3CAR gene Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 1
- 229940044665 STING agonist Drugs 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- RFCBNSCSPXMEBK-INFSMZHSSA-N c-GMP-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 RFCBNSCSPXMEBK-INFSMZHSSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229920006176 crosslinked polyethyleneglycol Polymers 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000021601 lentivirus infection Diseases 0.000 description 1
- 238000010859 live-cell imaging Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960005358 monensin Drugs 0.000 description 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides a chimeric antigen receptor and uses thereof. The chimeric antigen receptor comprises: a first fragment, said first fragment being a NKG2D full-length sequence; a second fragment, wherein the first fragment is a full-length sequence of DAP10, and the first fragment is connected with the second fragment; an intracellular signal transduction domain, the N-terminus of the intracellular signal transduction domain being linked to the C-terminus of the first fragment or the second fragment. The chimeric antigen receptor disclosed by the invention can recognize multiple NKG2D ligands, immune cells expressing the chimeric antigen receptor disclosed by the invention can recognize and kill multiple tumors expressing the NKG2D ligands in a targeted manner, can be used for developing universal immune cell products, and realizes treatment of multiple tumor indications by a CAR-T or CAR-NK product, and has a good clinical application prospect.
Description
Technical Field
The invention relates to the field of biopharmaceuticals, in particular to a chimeric antigen receptor and application thereof, and in particular relates to a chimeric antigen receptor capable of recognizing NKG2D multiple ligands, and corresponding nucleic acid molecules, expression vectors, lentiviral vectors, transgenic immune cells, pharmaceutical compositions and application thereof.
Background
In recent years, chimeric antigen receptor T (CHIMERIC ANTIGEN receptor T, CAR-T) cells have achieved tremendous success in hematological malignancy therapy. CAR-T cells still present a number of challenges in clinical applications, for example, exhibiting low efficacy in the treatment of solid tumors; tumors have off-target effects and drug resistance through immune escape mechanisms that lose antigen. CAR-T cells require autologous adoptive cell transplantation, otherwise allogeneic T cells may lead to Graft Versus Host Disease (GVHD); is easy to produce adverse reactions such as cytokine storm, neurotoxicity and the like, and causes harm to the life of patients. Recent studies indicate that CAR-NK cells may overcome the above-mentioned drawbacks of CAR-T cells and show a significant anti-tumor effect.
In vivo application of the CAR-NK cells generally does not cause cytokine storm, the NK cells do not need strict HLA matching, and the potential of GVHD is not caused; NK cells do not need antigen presentation and are not limited by MHC, so that the NK cells can play a role in directly killing tumor cells; the CAR-NK cells can accurately identify tumors through the installed 'CAR', can also identify corresponding ligand activation signals of the tumor cells through the activation receptor expressed by the CAR-NK cells, kills the tumors in a CAR independent mode, has a broad anti-tumor spectrum, and can prevent the tumors from losing through antigen or MHC molecules to generate off-target effect and immune escape. The CAR-NK cells may also be used in combination with antibodies, whereby the fcγrii (CD 16) on their surface binds to the Fc-segment of the antibody, thereby amplifying the anti-tumor efficacy of the CAR-NK cells by means of antibody-dependent cellular cytotoxicity (ADCC). Therefore, the CAR-NK cells have wide application prospect in anti-tumor treatment and become hot spots in the field of development of cellular immunotherapy.
Traditional CAR-T or CAR-NK technologies mostly target recognition of tumors by expressing single chain antibodies (ScFv) that specifically recognize specific tumor antigens, initiate activation signals of intracellular segments, mediating killing of tumor cells. However, traditional ScFv recognizes a tumor single antigen, off-target effects and therapeutic drug resistance or relapse may occur when the tumor antigen is lost, limiting further applications of CAR-T or CAR-NK technology.
The complex immunosuppressive microenvironment within a solid tumor is also one of the limiting factors that severely affect the anti-tumor effect of CAR-T or CAR-NK cells. Myeloid-derived suppressor cells (Myeloid-derived suppressor cells, MDSCs) are a population of myeloid-derived suppressor cells that suppress the anti-tumor effects of immune cells in the body. Studies have shown that MDSCs down-regulate the expression of NKG2D by membrane binding TGF-beta, thereby inhibiting the function of NK cells. MDSCs can also induce Treg cell expansion, promoting its negative effects on immunity. In addition, MDSCs suppress T cell immune responses and proliferation by, for example, generating reactive oxygen species. Therefore, how to overcome the immunosuppression of MDSCs on immune cells, particularly CAR-T or CAR-NK cells for feedback therapy, within the tumor microenvironment has become a research and development hotspot that breaks through the bottleneck of solid tumor immunotherapy.
Thus, there remains a need to develop new immune cell modification techniques to further enhance the therapeutic effect of CAR-T or CAR-NK.
Disclosure of Invention
The present invention aims to solve at least one of the technical problems existing in the prior art to at least some extent. Therefore, the chimeric antigen receptor provided by the invention can recognize multiple NKG2D ligands, and the immune cells modified by the chimeric antigen receptor not only can target and recognize and kill multiple tumors expressing the NKG2D ligands, but also can obviously improve the killing efficiency of MDSCs, further eliminate the negative regulation effect of the MDSCs on the immune cells, reverse the tumor immunosuppression microenvironment and ensure that the immune cells can play an anti-tumor role more effectively in organisms. The chimeric antigen receptor can be used for developing a universal immune cell product, realizes the treatment of various tumor indications by a CAR-T or CAR-NK product, and has good clinical application prospect.
The present invention has been completed based on the following work of the inventors:
NK cell receptors have the characteristic of broad specific recognition, and the ligands recognized by their activating receptors are expressed in most blood system tumors and solid tumors, but are hardly expressed in normal cells. Therefore, NK cell receptor is selected as antigen binding domain of chimeric antigen receptor, and immune cells are further modified by the chimeric antigen receptor gene, so that the obtained immune cells may have wider tumor recognition spectrum.
In order to obtain the CAR-immune cells with improved performance, the inventor creatively selects the full-length sequence of NKG2D and the full-length sequence of DAP10 to construct a chimeric antigen receptor structure capable of widely combining with various ligands of NKG 2D; meanwhile, the intracellular segment of the DAP10 molecule is ingeniously used as a chimeric antigen receptor intracellular region activating sequence to exert the effect of a co-stimulatory domain. Based on this, the inventors have obtained a chimeric antigen receptor that can widely recognize NKG2D ligands.
Further test results show that: immune cells (such as NK cells) modified by the chimeric antigen receptor gene can recognize various ligands of NKG2D, target and recognize and kill various hematological tumors and solid tumor cells expressing the NKG2D ligands, and have the characteristics of a general CAR-immune cell product.
MDSCs interact with immune cells (e.g., T cells, NK cells, dendritic cells, macrophages, etc.) and suppress the immune response of the body. In liver cancer mice, MDSCs cells are able to inhibit the expression of NK cell surface receptor NKG2D and IFN- γ production, inducing NK cell disability. The inventors have unexpectedly found that immune cells (e.g., NK cells) modified with the chimeric antigen receptor genes of the invention can not only target killing NKG2D ligand positive tumor cells, but also effectively kill MDSCs. In a mouse model of tumor-bearing human liver cancer H7402 cells containing MDSCs, tail vein reinfusion immune cells or treatment by chimeric antigen receptor immune cells of the invention, the results show that: the chimeric antigen receptor immune cells can effectively eliminate the negative regulation MDSCs cells which play a role in inhibiting immune effector cells in tumor microenvironment, so that the immune cells in the tumor microenvironment are saved from being inhibited by the MDSCs, the immune cells (including the immune cells and the immune cells which are not subjected to genetic modification) can play an anti-tumor role more effectively, and the clinical curative effect of immune cell products is further improved.
Thus, in a first aspect of the invention, the invention provides a chimeric antigen receptor. The chimeric antigen receptor comprises: a first fragment, said first fragment being a NKG2D full-length sequence; a second fragment, wherein the first fragment is a full-length sequence of DAP10, and the first fragment is connected with the second fragment; an intracellular signal transduction domain, the N-terminus of the intracellular signal transduction domain being linked to the C-terminus of the first fragment or the second fragment. The chimeric antigen receptor of the invention has stronger and wider NKG2D ligand binding activity, and immune cells expressing the chimeric antigen receptor of the invention can effectively target and identify and kill various blood tumor and solid tumor cells expressing the NKG2D ligand, and has the characteristics of universal CAR-immune cell products.
In a second aspect of the invention, the invention provides a nucleic acid molecule. The nucleic acid molecule comprises a first nucleic acid molecule encoding the chimeric antigen receptor of the first aspect of the invention. The immune cells carrying the nucleic acid molecules express the chimeric antigen receptor of the first aspect of the invention, and the chimeric antigen receptor can further recognize and bind with various ligands of NKG2D, thereby realizing the targeted recognition of various blood tumor and solid tumor cells expressing the NKG2D ligands by the immune cells and further exerting the killing activity thereof.
In a third aspect of the invention, the invention provides an expression vector. The expression vector carries the nucleic acid molecule of the second aspect of the invention. Thus, the chimeric antigen receptor of the first aspect of the present invention is expressed in cells using the constructed expression vector, and is efficiently expressed and obtained.
In a fourth aspect of the invention, the invention provides a transgenic immune cell. The transgenic immune cell expresses the chimeric antigen receptor of the first aspect of the invention, or carries the nucleic acid molecule of the second aspect of the invention or the expression vector of the third aspect of the invention. The transgenic immune cell can be widely used for targeted recognition and killing of various solid tumors or hematological tumors expressing NKG2D ligands, can be used for effectively killing immunosuppressive cells MDSCs in tumor microenvironment, is a universal immune cell product, has good clinical curative effect, can be used for treating various tumor diseases, and has good clinical application prospect.
In a fifth aspect of the invention, the invention provides a pharmaceutical composition. The pharmaceutical composition comprises the chimeric antigen receptor of the first aspect of the invention, the nucleic acid molecule of the second aspect of the invention, the expression vector of the third aspect of the invention or the transgenic immune cell of the fourth aspect of the invention. The obtained pharmaceutical composition can be further used for preventing or treating various tumor diseases.
In a sixth aspect of the invention, the invention provides a use for preparing a medicament. Use of a chimeric antigen receptor of the first aspect of the invention, a nucleic acid molecule of the second aspect of the invention, an expression vector of the third aspect of the invention, a transgenic immune cell of the fourth aspect of the invention or a pharmaceutical composition of the fifth aspect of the invention in the manufacture of a medicament for the prevention or treatment of a tumor. The chimeric antigen receptor and the corresponding nucleic acid molecules, expression vectors, transgenic immune cells or pharmaceutical compositions can be further prepared into medicines which can be clinically used for preventing or treating diseases.
Those skilled in the art will appreciate that the features and advantages described above for chimeric antigen receptors, nucleic acid molecules, expression vectors, lentiviral vectors, transgenic immune cells and pharmaceutical compositions are equally applicable for this use and will not be described in detail herein.
Additional aspects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention.
Drawings
The foregoing and/or additional aspects and advantages of the invention will become apparent and may be better understood from the following description of embodiments taken in conjunction with the accompanying drawings in which:
FIG. 1 is a schematic diagram showing the structure of the genetic elements of the chimeric antigen receptor of example 1 of the present invention;
FIG. 2 is a graph showing the measurement of the expression of MICA/B of the NKG 2D-ligand of the human hepatoma cell line, the breast cancer cell line and the non-small cell lung cancer cell line according to example 2 of the present invention, wherein H7402, huh7 and SMMC-7721 are human hepatoma cell lines, MCF-7 is human breast cancer cell line and A594 is human non-small cell lung cancer cell line;
FIG. 3 is a graph showing the results of examining the in vitro killing activity of the CAR-NK92 cells of the example 2 of the present invention;
FIG. 4 is a graph showing the results of examining the expression levels of CD107a, performin and Granzyme B of the CAR-NK92 cells of example 2 of the present invention;
FIG. 5 is a graph showing the results of examining IFN-. Gamma.secretion levels from CAR-NK92 cells of example 2 of the present invention;
FIG. 6 is a graph showing the results of examining the survival rate of CAR-NK92 cells in example 2 of the present invention;
FIG. 7 is a graph of proliferation of CAR-NK92 cells of example 2 of the present invention, the abscissa indicates the time of cell culture in days;
FIG. 8 is a graph showing the detection of the expression of the NKG 2D-ligands MICA/B and ULBP2/5/6 of the human ovarian cancer cell lines SKOV3 and A1847 of example 3 of the present invention;
FIG. 9 is a graph showing the tumor inhibition effect of the CAR-NK92 cells of the embodiment 3 on a human ovarian cancer SKOV3 cell tumor-bearing mouse model;
FIG. 10 is a graph showing the tumor-inhibiting effect of the CAR-NK92 cells of example 3 of the present invention on a mouse model with tumor cells of human ovarian cancer A1847;
FIG. 11 is a graph showing the tumor-inhibiting effect of peripheral blood derived CAR-NK cells of example 3 of the present invention on a mouse model with tumor cells of human pancreatic cancer HPAF-II, wherein PBS represents PBS group, NK represents a control group of NK cells without genetic modification, and CAR-NK-4E6, CAR-NK-8E6, and CAR-NK-16E6 represent a treatment group of CAR-NK cells with injection doses of 4X 10 6、8×106 and 1.6X10 7 CAR-NK cells/mouse, respectively;
FIG. 12 is a graph of the results of examining the killing activity of MDSCs by CAR-NK92 cells of example 4 of the present invention;
FIG. 13 is a graph showing the tumor-inhibiting effect of the CAR-NK92 cells of example 4 of the present invention on tumor-bearing mice model of human liver cancer H7402 cells containing MDSCs.
Detailed Description
Embodiments of the present invention are described in detail below. The following examples are illustrative only and are not to be construed as limiting the invention.
It should be noted that the terms "first," "second," and "second" are used for descriptive purposes only and are not to be construed as indicating or implying a relative importance or implying a number of technical features being indicated. Thus, a feature defining "a first" or "a second" may explicitly or implicitly include one or more such feature. Further, in the description of the present invention, unless otherwise indicated, the meaning of "a plurality" is two or more.
The endpoints and any values of the ranges disclosed herein are not limited to the precise range or value, and are understood to encompass values approaching those ranges or values. For numerical ranges, one or more new numerical ranges may be found between the endpoints of each range, between the endpoint of each range and the individual point value, and between the individual point value, in combination with each other, and are to be considered as specifically disclosed herein.
Terms and definitions
In this document, the terms "comprise" or "include" are used in an open-ended fashion, i.e., to include what is indicated by the present invention, but not to exclude other aspects.
In this document, the terms "optionally," "optional," or "optionally" generally refer to the subsequently described event or condition may, but need not, occur, and the description includes instances in which the event or condition occurs, as well as instances in which the event or condition does not.
As used herein, the term "LTR", which is equivalent to "long TERMINAL REPEATED", and equivalent to "long terminal repeat", refers to a retrovirus having one long terminal repeat (5 '-LTR and 3' -LTR) at each end of its genome. It does not code protein, but contains regulatory elements of promoter and enhancer, etc., LTR in virus genome can be transferred to adjacent place of cell protooncogene, so that these protooncogenes can be activated under the action of LTR strong promoter and enhancer, and can convert normal cell into cancer cell.
As used herein, "super IL-15" is a cytokine that promotes T cell and NK cell survival, proliferation, and is a fusion protein, including IL-15Rα and IL-15.IL-15 and IL-2 share IL-2/15Rβγc receptor, IL-15 and IL-15Rα form dimer and then combine with IL-15Rβγc to activate downstream JAK1/JAK3 and STAT3/STAT5 signal channels, thereby promoting proliferation and activation of NK cells. At present, cytokines such as IL-2, IL-15 and the like are often used clinically to prolong the survival time of NK cells in vivo, but the cytokine support treatment can also bring corresponding side effects. Systemic IL-2 therapy has been shown to induce activation of Treg cells and to bring about severe vascular leak syndrome and neurotoxicity. Whereas systemic administration of IL-15 treatment affects mainly NK cells, γδ T cells and CD8 memory T cells, IL-15 causes symptoms such as hypotension and thrombocytopenia in a dose dependent manner and leads to neutropenia. Thus, IL-15 is a safer option than IL-2, but the systemic toxicity from IL-15 is still not negligible.
Herein, the term "single chain antibody", equivalent to "SINGLE CHAIN FV", equivalent to "scFv", is a small molecule antibody formed by joining an immunoglobulin heavy chain variable region (V H) and a light chain variable region (V L) via a linker peptide. The linker peptides used to make scFv must be flexible enough to ensure that V H and V L are free to fold, giving the antibody binding region the correct configuration.
In this context, the term "(G 4S)n" is identical to "(Gly 4Ser)n" means that 4 glycine and 1 serine are repeated N times, and is a class of connecting peptides which are widely used at present, and can be located between the C-terminus of V H and the N-terminus of V L, and also between the C-terminus of V L and the N-terminus of V H) (G 4S)3 is currently commonly used, wherein glycine is the amino acid with the smallest molecular mass and the shortest side chain, which can increase the flexibility of the side chain, serine is the amino acid with the strongest hydrophilicity, which can increase the hydrophilicity of the connecting peptide, (G 4S)3 has better stability and vitality).
As used herein, the term "linker" refers to a gap junction basic structural unit, typically consisting of six identical or similar transmembrane proteins, and a gap junction basic structural unit consisting of six identical or similar transmembrane proteins. In some specific cases, this includes but is not limited to "2A peptide". The 2A peptide is a short peptide (about 18-25 amino acids) of viral origin, commonly referred to as a "self-cleaving" peptide, which allows the production of multiple proteins from a single transcript. The 2A peptide does not completely "self-cleave" but rather acts by allowing the ribosome to skip synthesis of glycine and proline peptide bonds at the C-terminus of the 2A element, ultimately resulting in separation of the 2A sequence end and downstream products. Wherein, the C-terminal of the upstream protein will add some additional 2A residues, while the N-terminal of the downstream protein will have additional proline. There are four commonly used 2A peptides, P2A, T2A, E2A and F2A, respectively, derived from four different viruses.
In this context, the term "vector" or "expression vector" generally refers to a nucleic acid molecule capable of insertion into a suitable host for self-replication, which transfers the inserted nucleic acid molecule into and/or between host cells. The vector may include a vector mainly used for inserting DNA or RNA into a cell, a vector mainly used for replicating DNA or RNA, and a vector mainly used for expression of transcription and/or translation of DNA or RNA. The carrier also includes a carrier having a plurality of functions as described above. The vector may be a polynucleotide capable of transcription and translation into a polypeptide when introduced into a suitable host cell. Typically, the vector will produce the desired expression product by culturing a suitable host cell comprising the vector.
The term "pharmaceutical composition" as used herein generally refers to unit dosage forms and may be prepared by any of the methods well known in the pharmaceutical arts. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. Generally, the compositions are prepared by uniformly and intimately bringing into association the active compound with liquid carriers, solid carriers, or both.
As used herein, the term "pharmaceutically acceptable excipients" may include any solvent, solid excipient, diluent or other liquid excipient, etc., suitable for the particular dosage form of interest. In addition to the extent to which any conventional adjuvant is incompatible with the chimeric antigen receptor, nucleic acid molecule, expression vector or transgenic immune cell of the invention, such as any adverse biological effects produced or interactions with any other component of the pharmaceutically acceptable composition in a deleterious manner, their use is also contemplated by the present invention.
As used herein, the term "administering" refers to introducing a predetermined amount of a substance into a patient by some suitable means. The chimeric antigen receptor, nucleic acid molecule, expression vector or transgenic immune cell or pharmaceutical composition of the invention may be administered by any common route, as long as it reaches the intended tissue. Various modes of administration are contemplated, including peritoneal, intravenous, intramuscular, subcutaneous, etc., but the invention is not limited to these illustrated modes of administration. Preferably, the compositions of the present invention are administered intravenously.
In this context, the term "treatment" refers to the use to obtain a desired pharmacological and/or physiological effect. The effect may be prophylactic in terms of completely or partially preventing the disease or symptoms thereof, and/or may be therapeutic in terms of partially or completely curing the disease and/or adverse effects caused by the disease. As used herein, "treating" encompasses diseases in mammals, particularly humans, including: (a) Preventing the occurrence of a disease or disorder in an individual susceptible to the disease but not yet diagnosed with the disease; (b) inhibiting disease, e.g., arresting disease progression; or (c) alleviating a disease, e.g., alleviating symptoms associated with a disease. As used herein, "treating" encompasses any administration of a drug or transgenic immune cell to an individual to treat, cure, alleviate, ameliorate, reduce or inhibit a disease in the individual, including, but not limited to, administration of a drug comprising a chimeric antigen receptor-containing cell described herein to an individual in need thereof.
Herein, "carbon end" and "C end" are synonymous; "Nitrogen end" and "N end" are synonymous.
The invention provides a chimeric antigen receptor capable of recognizing NKG2D multiple ligands, and corresponding nucleic acid molecules, expression vectors, transgenic immune cells, pharmaceutical compositions and uses thereof, which are respectively described in detail below.
Chimeric antigen receptor
The present invention provides a chimeric antigen receptor. The chimeric antigen receptor comprises: a first fragment, said first fragment being a NKG2D full-length sequence; a second fragment, wherein the first fragment is a full-length sequence of DAP10, and the first fragment is connected with the second fragment; an intracellular signal transduction domain, the N-terminus of the intracellular signal transduction domain being linked to the C-terminus of the first fragment or the second fragment.
According to the embodiments of the present invention, the inventors creatively linked the full-length sequence of NKG2D and the full-length sequence of DAP10 to obtain chimeric antigen receptor with stronger and wider NKG2D ligand binding activity. Therefore, the immune cells expressing the chimeric antigen receptor disclosed by the invention can effectively target and identify and kill various hematological tumors and solid tumor cells expressing NKG2D ligands, have the characteristics of a general CAR-immune cell (such as a CAR-NK product) product, and can effectively kill immunosuppressive cells MDSCs in a tumor microenvironment and effectively reverse the tumor immunosuppression microenvironment.
According to an embodiment of the present invention, the chimeric antigen receptor may further include at least one of the following technical features:
According to an embodiment of the invention, the NKG2D full-length sequence has the sequence set forth in SEQ ID NO:1, and a polypeptide having the amino acid sequence shown in 1.
According to an embodiment of the invention, the full length DAP10 sequence has the sequence set forth in SEQ ID NO:2, and a polypeptide having the amino acid sequence shown in 2.
According to an embodiment of the invention, the N-terminus of the intracellular signaling domain is linked to the C-terminus of the first fragment.
According to an embodiment of the invention, the intracellular signaling domain is an intracellular segment of a cd3ζ molecule.
According to an embodiment of the invention, the intracellular segment of the CD3 zeta molecule has the sequence as set forth in SEQ ID NO:3, and a polypeptide having the amino acid sequence shown in 3.
Nucleic acid molecules
The present invention provides a nucleic acid molecule. The nucleic acid molecules include a first nucleic acid molecule encoding the chimeric antigen receptor described above. The immune cells carrying the first nucleic acid molecules can express the chimeric antigen receptor, and after the chimeric conversion receptor recognizes various NKG2D ligands, the immune cells are activated, so that the immune cells can realize the targeted recognition of tumors expressing the NKG2D ligands and can perform killing effect.
According to an embodiment of the invention, the first nucleic acid molecule comprises nucleic acid molecule 1 and nucleic acid molecule 2; said nucleic acid molecule 1 for encoding said first fragment and said intracellular signaling domain, and said nucleic acid molecule 2 for encoding said second fragment; or said nucleic acid molecule 1 is used to encode said first fragment and said nucleic acid molecule 2 is used to encode said second fragment and said intracellular signaling domain.
According to an embodiment of the invention, the nucleic acid molecule 1 has the sequence as set forth in SEQ ID NO:4, said nucleic acid molecule 2 having a nucleotide sequence as set forth in SEQ ID NO:5, a nucleotide sequence shown in seq id no; or the nucleic acid molecule 1 has the sequence as set forth in SEQ ID NO:6, said nucleic acid molecule 2 having a nucleotide sequence as set forth in SEQ ID NO: 7.
According to an embodiment of the invention, the first nucleic acid molecule further comprises a nucleic acid molecule 3, the nucleic acid molecule 3 encoding a first linker, the nucleic acid molecule 1 and the nucleic acid molecule 2 being linked by the nucleic acid molecule 3.
According to an embodiment of the invention, the first linker is selected from at least one of P2A, T2A, E a and F2A.
Thus, immune cells carrying the nucleic acid molecules described above can express the chimeric antigen receptor described above. When the nucleic acid molecule comprises a linker of at least one of P2A, T2A, E a and F2A, the linker and the NKG2D and DAP10 fragments linked by the linker are expressed in immune cells. Further, NKG2D and DAP10 polypeptide fragments are cleaved by the linker polypeptide, thereby assembling a complex with NKG2D ligand binding activity.
According to an embodiment of the present invention, the first linker is P2A.
According to an embodiment of the invention, the first linker has the sequence as set forth in SEQ ID NO:8, and a polypeptide having the amino acid sequence shown in FIG. 8.
In some specific embodiments, the nucleic acid molecule 3 has a sequence as set forth in SEQ ID NO: 9.
In some specific embodiments, the first nucleic acid molecule has a sequence as set forth in SEQ ID NO:10, and a nucleotide sequence shown in seq id no.
According to an embodiment of the invention, the above-mentioned nucleic acid molecule further comprises a second nucleic acid molecule encoding a fusion protein comprising IL-15Rα and IL-15.
According to an embodiment of the invention, the N-terminus of IL-15Rα is linked to the C-terminus of IL-15, or the N-terminus of IL-15 is linked to the C-terminus of IL-15Rα.
According to an embodiment of the invention, the IL-15Rα has the amino acid sequence as set forth in SEQ ID NO:11, and a polypeptide comprising the amino acid sequence shown in seq id no.
According to an embodiment of the invention, the IL-15 has the sequence as set forth in SEQ ID NO:12, and a polypeptide having the amino acid sequence shown in FIG. 12.
According to embodiments of the invention, the IL-15Rα of the invention is an IL-15 receptor α chain comprising a transmembrane region; the IL-15 of the present invention is an IL-15 mature peptide, thereby achieving membrane expression of IL-15Rα and IL-15, and further forming an IL-15Rα and IL-15 complex, abbreviated herein as "super IL-15". Compared with the secretory IL-15 or the secretory super IL-15, the expression quantity in cells is controllable, the expression area is controllable, the range of acting cells is controllable, and side effects caused by systemic administration of recombinant IL-15 or super IL-15 or repeated and repeated administration can be avoided. Whereby, co-expression of said super IL-15 with the chimeric antigen receptor of the invention onto the surface of an immune cell, on the one hand, increases the persistence of said immune cell in vivo and the viability in vivo; on the other hand, unexpectedly, the tumor killing activity of the immune cells can be significantly improved. Makes it possible to develop universal, safe and effective immune cell product.
According to an embodiment of the invention, the fusion protein further comprises a connecting peptide.
According to an embodiment of the invention, the C-terminus of the IL-15Rα is linked to the N-terminus of the linker peptide, which is linked to the N-terminus of the IL-15; or the C-terminal of the IL-15 is connected with the N-terminal of the connecting peptide, and the C-terminal of the connecting peptide is connected with the N-terminal of the IL-15 Ralpha.
According to an embodiment of the invention, the linking peptide is selected from at least one of (G4S)n、ESGRSGGGGSGGGGS、EGKSSG SGSESKST、EGKSSGSGSESKSTQ、GSTSGSGKSSEGKG、KESGSVSSEQLAQFRSLD、ESGSVSSEELAFRSLD、SGGGSGGGGSGGGGSGGGGSGGGSLQ, n is an integer other than zero.
According to an embodiment of the invention, the linking peptide is selected from (G 4S)n, n is any integer between 2 and 6).
According to an embodiment of the invention, the connecting peptide is (G 4S)3.
According to an embodiment of the invention, the connecting peptide is SGGGSGGGGSGGGGSGGGGSGGGSLQ.
According to an embodiment of the invention, the fusion protein has the sequence as set forth in SEQ ID NO:13, and a nucleotide sequence shown in seq id no.
In some specific embodiments, the second nucleic acid molecule has a sequence as set forth in SEQ ID NO:14, and a nucleotide sequence shown in seq id no.
Therefore, the expression quantity, the expression region and the action cell range of the super IL-15 are further optimally controlled, and the safety of the obtained genetically modified immune cells is obviously improved.
According to an embodiment of the invention, the nucleic acid molecule further comprises a third nucleic acid molecule encoding a second linker, the first nucleic acid molecule and the second nucleic acid molecule being linked by the third nucleic acid molecule.
According to an embodiment of the invention, the second linker is selected from at least one of P2A, T2A, E a and F2A.
According to an embodiment of the present invention, the second linker is P2A.
According to an embodiment of the invention, the second linker has the sequence as set forth in SEQ ID NO:8, and a polypeptide having the amino acid sequence shown in FIG. 8.
According to an embodiment of the invention, the third nucleic acid molecule has the sequence as set forth in SEQ ID NO: 9.
Therefore, the super IL-15 nucleic acid molecule and the nucleic acid encoding the chimeric antigen receptor of the invention are simultaneously expressed in cells according to fixed proportion, so that the relative expression quantity of the super IL-15 and the chimeric antigen receptor in a single cell is controlled, and the safety of genetically modified immune cells is further improved.
In some specific embodiments, the nucleic acid molecule has a sequence as set forth in SEQ ID NO:15, and a nucleotide sequence shown in seq id no.
It is noted that, for the nucleic acid molecules mentioned herein, one skilled in the art will understand that either one or both of the complementary double strands are actually included. For convenience, although only one strand is shown in most cases herein, the other strand complementary thereto is actually disclosed. In addition, the molecular sequence in the present invention includes a DNA form or an RNA form, and disclosure of one of them means that the other is also disclosed.
Expression vector
The invention provides an expression vector. The expression vector carries the nucleic acid molecule described above. Thus, the expression vector constructed can express the chimeric antigen receptor of the present invention in a receptor cell.
In the case of ligating the above-mentioned nucleic acid molecule to an expression vector, the nucleic acid molecule may be directly or indirectly linked to control elements on the expression vector, as long as these control elements are capable of controlling translation, expression, etc. of the nucleic acid molecule. Of course, these control elements may be directly from the carrier itself or may be exogenous, i.e. not from the carrier itself. Of course, the nucleic acid molecule may be operably linked to a control element.
According to an embodiment of the invention, the expression vector is a non-pathogenic viral vector.
According to an embodiment of the invention, the non-pathogenic viral vector is optionally one of a retroviral vector, a chronic viral vector and an adeno-associated viral vector.
According to an embodiment of the invention, the non-pathogenic viral vector is a lentiviral vector.
According to embodiments of the invention, expression of the chimeric antigen receptor of the invention in immune cells may be achieved after introduction of the lentiviral vector into the recipient cell in some embodiments.
As used herein, the term "operably linked" refers to the linkage of a foreign gene to a vector such that control elements within the vector, such as transcription and translation control sequences, and the like, are capable of performing their intended functions of regulating transcription and translation of the foreign gene. The usual vectors may be, for example, viral vectors, plasmids, phages and the like. After the expression vector according to some embodiments of the present invention is introduced into a suitable recipient cell, the expression of the nucleic acid molecule described above can be effectively achieved under the mediation of a regulatory system, thereby achieving in vitro mass-production of the protein encoded by the nucleic acid molecule.
Cells
The present invention provides a transgenic immune cell. The transgenic immune cells express the chimeric antigen receptor; or carrying the nucleic acid molecules described above, the expression vectors described above. Thus, the obtained transgenic immune cells have obviously improved tumor killing activity and better safety. Furthermore, the development of a universal, safe and effective immune cell product is possible, and the treatment of various tumor indications by a CAR-T or CAR-NK product is further realized, so that the transgenic immune cell has good clinical application prospect.
According to an embodiment of the invention, the transgenic immune cells express both the chimeric antigen receptor and a fusion protein identical to the fusion protein expressed in the nucleic acid molecule described previously. Therefore, compared with immune cells modified by chimeric antigen receptor genes, the transgenic immune cells express the membrane-binding super IL-15 on the surface of cell membranes, and the obtained transgenic immune cells have the advantages of improved in-vivo and in-vitro proliferation capacity, remarkably enhanced tumor cell killing activity and synergistic effect.
Furthermore, the inventors have further found that at the cellular level, the transgenic immune cells of the invention exhibit significantly increased degranulation levels and killing functions, as well as significantly increased IFN-gamma and TNF-alpha secretion capacity. At animal level, the transgenic immune cells of the invention also show obviously enhanced in vivo tumor inhibiting effect, and can kill the immune suppression cells MDSCs in tumor microenvironment, thereby effectively reversing tumor immune suppression microenvironment. Thus, the expression of the full-length NKG2D sequence and the full-length DAP10 sequence of the invention enables NK cells to recognize tumors expressing the NKG2D ligand more accurately and effectively, while the gene modification strategy of the membrane-bound super IL-15 of the invention can improve the persistence and the viability of the transgenic immune cells of the invention in vivo, and the two gene modification strategies also observe synergistic beneficial effects unexpectedly in the invention. Namely, the gene modification strategy of the invention can obviously improve the tumor killing activity of immune cells, so that the development of a universal, safe and effective immune cell product is possible, and the treatment of various tumor indications by one CAR-T or CAR-NK product is further realized.
According to an embodiment of the invention, the transgenic immune cell is obtained by introducing the expression vector into an immune cell.
According to an embodiment of the present invention, the immune cells are selected from at least one of any one of T cells, NK cells, NKT cells, γδ T cells, macrophages, peripheral blood NK cells, umbilical cord blood NK cells, and iPSC-derived immune cells. The chimeric antigen receptor of the present invention can be expressed on the surface of immune cells such as T, NK, NKT, γδt, macrophage, iPSC, etc., by transduction of these immune cells with an expression vector (lentiviral vector).
In some specific embodiments, the immune cells are selected from at least one of NK cells, peripheral blood NK cells, umbilical cord blood and iPSC-derived NK cells, NK92 cells.
In some more specific embodiments, the immune cells are optionally derived from any one of the NK cell lines.
According to embodiments of the present invention, the immune cells of the present invention have better clinical efficacy and safety and broader clinical applicability than immune cells that sequentially or simultaneously administer single chain antibodies to recognize specific tumor antigens at comparable doses and in the same manner of administration.
Pharmaceutical composition
The invention provides a pharmaceutical composition. The pharmaceutical composition comprises the chimeric antigen receptor, the nucleic acid molecule, the expression vector or the transgenic immune cell. The pharmaceutical composition thus obtained is further used for the treatment of tumors.
According to an embodiment of the present invention, the pharmaceutical composition further comprises: pharmaceutically acceptable auxiliary materials.
Those skilled in the art will appreciate that the features and advantages described above for chimeric antigen receptors, nucleic acid molecules, expression vectors, transgenic immune cells are equally applicable to the pharmaceutical compositions and will not be described in detail herein.
Use of the same
The invention provides the use of the chimeric antigen receptor, the nucleic acid molecule, the expression vector, the transgenic immune cell or the pharmaceutical composition in the preparation of medicaments for preventing or treating tumors.
According to an embodiment of the invention, the tumor is a solid tumor or a hematological tumor.
According to an embodiment of the invention, the solid tumor is a tangible tumor occurring in an organ. The tangible tumors occurring in the viscera include, but are not limited to, at least one of pancreatic cancer, ovarian cancer, mesothelioma, liver cancer, cholangiocarcinoma, gastric cancer, esophageal cancer, colorectal cancer, lung cancer, head and neck cancer, cervical cancer, glioma, renal cancer, breast cancer, prostate cancer and melanoma.
According to an embodiment of the invention, the hematological neoplasm comprises at least one selected from the group consisting of acute myeloid leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, hodgkin's lymphoma, non-hodgkin's lymphoma, and multiple myeloma.
According to some alternative embodiments of the invention, the hematological neoplasm comprises at least one selected from acute myeloid leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, hodgkin's lymphoma, non-hodgkin's lymphoma, and multiple myeloma within the blood cell and hematopoietic system.
Method for preventing or treating tumor
The present invention provides a method of treating and/or preventing an immune system disorder. According to an embodiment of the invention, the method comprises: administering to a subject a pharmaceutically acceptable amount of the transgenic immune cell described above or the pharmaceutical composition described above.
The effective amount of the transgenic immune cells and pharmaceutical compositions of the present invention may vary depending on the mode of administration, the severity of the disease to be treated, and the like. Preferably, the selection of an effective amount can be determined by one of ordinary skill in the art based on a variety of factors (e.g., by clinical trials). Such factors include, but are not limited to: pharmacokinetic parameters of the active ingredient such as bioavailability, metabolism, half-life etc.; the severity of the disease to be treated in the patient, the weight of the patient, the immune status of the patient, the route of administration, etc. For example, separate doses may be administered several times per day, or the dose may be proportionally reduced, as dictated by the urgent need for the treatment of the condition.
The details of the sequences involved in the present invention are shown in Table 1.
Table 1: nucleotide/amino acid sequence specification table
The scheme of the present invention will be explained below with reference to examples. It will be appreciated by those skilled in the art that the following examples are illustrative of the present invention and should not be construed as limiting the scope of the invention. The examples are not to be construed as limiting the specific techniques or conditions described in the literature in this field or as per the specifications of the product. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
In the following examples, the chimeric antigen receptor sequences comprise: NKG2D full-length sequence (nucleotide sequence shown as SEQ ID NO: 7), linker protein DAP10 full-length sequence (nucleotide sequence shown as SEQ ID NO: 5) and intracellular signal transduction molecule CD3 zeta (nucleotide sequence shown as SEQ ID NO: 16) and IL-15-linker-IL-15 Ralpha (nucleotide sequence shown as SEQ ID NO: 14) gene fragment connected by P2A (nucleotide sequence shown as SEQ ID NO: 9). The structural schematic diagram of the genetic element is shown in figure 1.
In the following examples, reference STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer.Oncoimmunology.2022Mar 21;11(1):2054105.doi:10.1080/2162402X.2022.2054105.PMID:35371622;PMCID:PMC8967397., detects the killing effect of effector cells on target cells by LDH release.
The "plasmid" and "vector" described in the following examples have the same meaning and are used interchangeably.
EXAMPLE 1 preparation of CAR-NK cells
In this example, the CAR-NK cells of the present invention were prepared as follows.
1.1 Construction of CAR expression plasmids
(1) The nucleotide sequence shown in SEQ ID NO.15 is synthesized through total gene synthesis, cloned to a lentiviral vector pCDG-EF1-MCS-TA 2-copGGFP through enzyme cutting sites XbaI and BamHI, and the pCDH-EF1a-CAR expression plasmid vector is obtained after sequencing verification is correct.
The structural schematic diagram of the genetic element of the chimeric antigen receptor of this example is shown in FIG. 1, and specific sequence information is shown in reference Table 1.
1.2 Packaging of lentiviruses and concentration of viral fluids
293T cells in the logarithmic growth phase were inoculated into 10cm cell culture dishes at 5X 10 6, 10mLDMEM medium was added and incubated overnight in a 5% CO 2 incubator at 37 ℃. When the cell density in the cell culture dish reached 80%, 10mL of fresh DMEM medium was replaced for virus packaging, and the cell culture dish was kept in an incubator for further use. Preparing a slow virus packaging system, adding psPAX 26 mug of slow virus packaging auxiliary plasmid and 6 mug of target gene carrier plasmid into 250 mug serum-free DMEM culture medium to prepare plasmid mixed solution, and uniformly mixing. Will 15 mu LAdded into 235 mu L of serum-free DMEM medium, and mixed uniformly. Will beThe mixed solution is added into the plasmid mixed solution at one time, mixed evenly and incubated for 15min at room temperature. The mixture was added to 293T cell culture dishes. After 24h, the culture dish was replaced with a 5% CO 2 incubator at 37℃for 48h, and the cell supernatant was collected, centrifuged at 400 Xg for 5min, the cell debris was removed, and the supernatant was filtered into a 50ml centrifuge tube with a 0.45 μm filter head. Adding 5 XPEG 8000 solution for concentrating virus liquid, reversing the centrifuge tube upside down, mixing, and standing in a refrigerator at 4deg.C overnight. Centrifuging at 4deg.C at 4000 Xg for 20min, discarding supernatant, adding appropriate amount of serum-free DMEM to resuspend virus precipitate, transferring into EP tube, and storing in refrigerator at-80deg.C.
1.3 Lentiviral titer assay
293T cells in the logarithmic growth phase were collected and the concentration was adjusted to 1X 10 5/mL. A24-well plate was used, and 1mL of the cell suspension (1X 10 5/well) was added to each well, and 3 added virus volume gradients were set. The cells were incubated overnight at 37℃in a 5% CO 2 incubator. The concentrated virus solution is diluted 10 times: a1 mL EP tube was used, 60. Mu.L of the virus concentrate was pipetted into the EP tube, diluted with 540. Mu. LDMEM medium and mixed well. 293T cells were replaced with fresh DMEM medium, 5. Mu.L, 50. Mu.L and 500. Mu.L of diluted virus solution were each aspirated and added to the corresponding wells, labeled, and the plates were returned to 37℃in a 5% CO 2 incubator. After 24h, the well plates were blotted for virus and 1mL fresh DMEM medium was added. After 72h, cells were harvested by pancreatin digestion, 293T cells were examined for GFP expression using a flow meter, and viral titers were converted according to the formula.
Titer(TU/ml)=100,000(target cells)×(%of GFP-positive cells/100)×10/volume of supernatant(in mL)。
1.4 Lentivirus infection of human NK92 cells
NK92 cells in the logarithmic phase of growth were aspirated, the cells were harvested by centrifugation at 100 Xg for 5min, and the cells were resuspended in an appropriate amount of alpha-MEM medium to adjust the cell density to 5X 10 5/mL. 5X 10 5 NK92 cells were inoculated into a 24-well plate, and 1mL of the virus concentrate and protamine (final concentration 8. Mu.g/mL) were mixed uniformly. Culturing in a 5% CO 2 incubator at 37deg.C. After 24h, the cell status was observed, the liquid was changed, the infected cells were transferred into EP tube, centrifuged at 100 Xg for 5min, the cells were resuspended in a small amount of fresh alpha-MEM medium, transferred into cell culture flasks, and cultured for a further 48h with 10mL of fresh alpha-MEM medium and IL-2 (final concentration of 200 IU/mL). Cells were transferred into a inflow tube, 3mL of 1 XPBS solution was added, 100 XPS was centrifuged for 5min, the supernatant was discarded, the cell pellet was sprung, and washed once again with 1 XPBS solution. The expression rate of GFP was measured using a flow meter. And continuing to expand the culture, and adjusting the state of NK92 cells after infection to expand. The infected NK92 cells were sorted by flow meter for GFP-positive CAR-NK92 cells for later experiments.
1.5 Infection of human peripheral blood primary-expanded NK cells with lentiviruses
Isolated Peripheral Blood Mononuclear Cells (PBMC) were inoculated into pre-coated flasks for culture, and induced culture using anti-CD 3 monoclonal antibodies and cytokines such as IL-2, see CN 202310035787.4. Lentiviral infection was performed as described above on day 7 of culture. Culture was continued after the change of fluid on day 9, and cells were harvested for in vivo experimental treatment by day 19.
Example 2 in vitro killing, proliferation and in vitro viability assays of CAR-NK cells
In this example, the inventors examined the killing activity of the CAR-NK cells of the invention obtained in example 1 against NKG2D ligand-positive tumors at the cellular level, proliferation and in vitro survival of the CAR-NK cells of the invention.
2.1CAR genetic modification enhances in vitro killing of NKG2D ligand positive tumors by NK92 cells
First, the expression of several tumor cell lines (hepatoma cell, breast cancer, non-small cell lung cancer) NKG2D ligand MICA/B was examined by flow cytometry, and the results are shown in FIG. 2. The liver cancer cell line H7402 cells, huh7 cells, breast cancer cell line MCF-7 cells and non-small cell lung cancer cell line A549 cells all express high level MICA/B, while the liver cancer cell line SMMC-7721 cells express lower and are basically negative. The inventor selects a MICA/B high-expression H7402 cell line and a SMMC-7721 cell which is basically expressed negatively as target cells to detect the influence of the CAR gene modification on the NK92 cell killing activity.
The specific method comprises the following steps: incubating NK92 and CAR-NK92 cells with liver cancer cell line H7402 or SMMC-7721 cells for 4H respectively, and detecting killing efficiency by an LDH release method; and simultaneously adding NKG2D antibody (Ab blockade) into a killing system for blocking, and respectively setting controls of NK92 and CAR-NK92 cell groups. The ratio of effector cells (NK cells) to target cells (tumor cells) was examined to be 10:1, 5:1 and 2.5:1.
The test results are shown in fig. 3: referring to inventive example 1, the killing efficiency of genetically modified inventive CAR-NK92 cells against MICA/B positive H7402 cells was significantly higher than NK92 cells at an effective target ratio of 10:1 and 5:1. The killing efficiency of the CAR-NK92 and NK92 cells to SMMC-7721 cells and H7402 cells after NKG2D antibody is added into a killing system is obviously reduced.
The test results show that the NKG2D chimeric antigen receptor of the invention has reasonable design and can effectively recognize the NKG2D ligand MICA/B; furthermore, NK cells modified by the NKG2D chimeric antigen receptor and the cell membrane expression IL-15 gene have obviously enhanced killing activity and show synergistic effect.
Further, CAR-NK92 and NK92 cells of the present invention were co-incubated with H7402 cells at an effective target ratio of 5:1, respectively, to examine the expression of NK cell killing effector molecules CD107a, granzyme B and Perforin (Perforin). The IgG group was a negative control group to which no flow antibody staining was added.
The specific method comprises the following steps: the CD107a group was added with 5. Mu.L PE-anti-human CD107a antibody (clone H4A3, biolegend), the positive control group with PMA (Sigma, final concentration 30 ng/mL) and ionomycin (ionomycin, sigma, final concentration 1. Mu.g/mL), the incubation was continued for 1H, and the blockers BFA and monensin (Biolegend, ratio 1:1000) were added and the incubation was continued for 3H. Cells were collected in a centrifuge tube, washed by centrifugation with 1 XPBS solution, resuspended in an appropriate amount of 1 XPBS solution, and examined for CD107a expression by flow cytometry. Granzyme B and Perforin groups, reinforcing fixed solution 100. Mu.L/tube, incubating at room temperature for 15min, adding 1 XPBS solution, centrifuging, washing, adding membrane penetrating solution 100. Mu.L/tube, and adding corresponding antibody (APC-anti-human Perforin, clone No. dG9; alexa)647-Anti-human Granzyme B, clone No. GB11, biolegend) incubated at room temperature for 30min, after centrifugation washing with 1 XPBS solution, appropriate amount of 1 XPBS solution was added to resuspend cells, and flow cytometry was used to detect the expression levels of Granzyme B and Perforin.
The test results are shown in FIG. 4: after co-incubation with MICA/B positive H7402 cells, the expression levels (mean fluorescence intensity MFI) of CAR-NK92 cells CD107a, performin and Granzyme B of the invention were all significantly higher than for NK92 group.
The above test results further verify that: the CAR gene modification strategy can obviously improve the degranulation level and the killing function of NK cells on NKG2D ligand positive tumor cells.
2.2CAR Gene modification enhances cytokine secretion levels in NK92 cells
The CAR-NK92 cells of the invention were further examined for changes in their IFN- γ and TNF- α secretion capacity by flow cytometry. The specific method comprises the following steps: incubating NK92 or CAR-NK92 cells and H7402 cells of a liver cancer cell line positive for NKG2D ligand for 4 hours, collecting NK92 or CAR-NK92 cells in a flow tube, and detecting the expression level of IFN-gamma and TNF-alpha in the cells of the NK92 or the CAR-NK92 cells by flow cytometry after fixation rupture treatment. The IgG group was a negative control group to which no flow antibody staining was added.
The test results are shown in fig. 5: the level of IFN-gamma and TNF-alpha expressed by the CAR-NK92 cells of the invention is obviously higher than that of the NK92 group.
The level of IFN-. Gamma.in the culture supernatant of NK92 cells incubated with H7402 cells was further examined by ELISA. The experimental results also show that the level of IFN-gamma secretion by the CAR-NK92 cells is significantly higher than that of the NK92 group (FIG. 5).
The above test results show that the CAR structure of the invention can obviously improve the secretion capacity of IFN-gamma and TNF-alpha when NK cells are contacted with NKG2D ligand positive tumor cells.
2.3CAR genetic modification promotes survival and proliferation of NK92 cells
The inventors further confirmed the promotion of proliferation and survival of NK92 cells by membrane-expressed IL-15. The specific method comprises the following steps: NK92 and CAR-NK92 cell plates of the same cell number were plated in 96-well plates, respectively, and different IL-2 concentrations (200 IU/ml, 20IU/ml and 0 IU/ml) were set, and flow cytometry was performed every 24 hours to detect apoptosis rate or trypan blue stained cell count every 48 hours. Flow cytometry detection of apoptosis rate was performed according to the procedure of the kit instructions (biankia, cat No. AP 101), briefly: cells were collected in EP tubes, washed once by centrifugation with 1xPBS solution, and resuspended. mu.L of Annexin V-FITC and 10. Mu.L of PI were added to each tube. After gentle vortexing, incubation for 5min at room temperature in the dark, and flow detection of resuspended cells. Cell viability was the proportion of Annexin V-FITC and PI staining double negative.
The results of NK cell viability investigation for 96h of culture are shown in fig. 6: NK92 group in the absence of IL-2 (IL-20 IU/ml), cell viability was significantly reduced from 24 hours to 72 hours when most cells had been apoptotic; while the CAR-NK92 group cells can still keep high cell viability even under the condition of completely removing IL-2, and few cells undergo apoptosis. It is suggested that IL-15 expressed in the membrane in CAR-NK92 plays an important role in promoting the survival of NK cells.
Further observations and cultures were made to day 8, and cell proliferation curves were plotted, with the results shown in fig. 7: the proliferation capacity of the CAR-NK92 cells is obviously higher than that of NK92 cells with the same IL-2 concentration under the condition of different IL-2 concentrations.
The test results above demonstrate that: unexpectedly, the inventors expect that the effect of the membrane-expressed IL-15 element of the invention on promoting NK cell proliferation is significantly enhanced when NK92 cells are cultured in vitro, compared with the effect of adding free IL-2 into a cell culture solution, thereby being more beneficial to NK92 proliferation culture in vitro and the industrialization of immune cell products of the invention.
Example 3CAR-NK cells have stronger anti-tumor ability in vivo
In this example, the inventors examined the killing activity of the CAR-NK cells of the invention obtained in example 1 against NKG2D ligand-positive tumors at animal level.
3.1 In vivo tumor-inhibiting effect of CAR-NK cells on ovarian cancer
The inventors first examined the expression of NKG2D ligands MICA/B and ULBP of human ovarian cancer cell lines SKOV3 and a1847, and the results are shown in fig. 8: SKOV3 expressed predominantly ULBP2/5/6, whereas A1847 cells expressed both MICA/B and ULBP2/5/6 higher. Thus, a human ovarian cancer mouse xenograft model was established with SKOV3 and a1847 cell lines, respectively, to observe the therapeutic effect of CAR-NK92 cells designed and prepared according to the present invention on ovarian cancer.
The specific method comprises the following steps: NCG mice at 6 weeks of age were selected for underarm subcutaneous tumor-bearing at a tumor-bearing dose of 2.5 x 10 6 cells/mouse. NK cell therapy was started on day 7 of tumor bearing. Tumor volume size was measured prior to treatment and randomly divided into PBS group, NK92 cell treatment group and CAR-NK92 cell treatment group according to tumor volume size. Mice in the treated group were given 1X 10 7 effector cells/mouse tail vein, untreated groups were given equal volumes of 1 XPBS, once every other week for 3 total treatments, and tail vein for 3 days for IL-2 (5X 10 4 IU/mouse). Tumor volume was measured every 3 or 4 days and tumor growth curves were drawn.
The test results are shown in fig. 9 and 10: (1) The therapeutic effect on SKOV3 ovarian cancer model showed that CAR-NK92 cells had a stronger tumor growth inhibiting effect than NK92, with a statistical tumor inhibition rate of 64.2% for the CAR-NK92 treated group at day 18 post-treatment, and 32.3% for the NK92 treated group (fig. 9). (2) The therapeutic effect on the a1847 ovarian cancer model showed that CAR-NK92 cells had a stronger tumor growth inhibiting effect than NK92, with a statistical tumor inhibition rate of 55.8% for the CAR-NK92 treated group at day 19 after treatment, and 42.9% for the NK92 treated group (fig. 10).
The above results illustrate: the NKG2D and membrane-bound IL-15-expressing CAR-NK92 cells have obviously enhanced in-vivo tumor inhibiting effect on NKG2D ligand positive tumors. The expression of the NKG2D-CAR enables NK cells to more accurately and effectively recognize tumors expressing the NKG2D ligand, and the membrane expression IL-15 gene modification can improve the persistence of the CAR-NK92 cells in the body and improve the viability of the CAR-NK92 cells in the body; the two are synergistic, and the anti-tumor effect of the CAR-NK92 cells is further enhanced.
3.2 In vivo tumor-inhibiting effect of primary CAR-NK cells on pancreatic cancer
The inventor establishes a human pancreatic cancer mouse xenograft tumor model by using a human pancreatic cancer cell line HPAF-II, prepares peripheral blood-derived CAR-NK cells by infecting human peripheral blood primary NK cells with the CAR lentivirus of the embodiment 1 of the invention, and observes the treatment effect of the CAR-NK cells on the pancreatic cancer model.
The specific method comprises the following steps: 6-week-old NCG mice were selected for underarm subcutaneous tumor loading and NK cell therapy was initiated when tumor volume reached 50mm 3. Tumor volume size was measured before treatment and randomly divided into PBS group, NK cell control group without genetic modification, and three CAR-NK cell treatment groups according to tumor volume size. Mice in the NK cell control group which are not subjected to gene modification are treated 1 time every 2 days for 3 times, the reinfusion dose of each tail vein is 4×10 6CD56+ NK cells, and the survival of the NK cells is maintained by intraperitoneal injection of IL-2 every 2 days; the CAR-NK cells are injected into the tail of mice in the CAR-NK cell treatment group intravenously, and the single treatment is carried out for 1 time, the doses are respectively 4 multiplied by 10 6、8×106 and 1.6multiplied by 10 7 CAR-NK cells/mouse, and the CAR-NK cells are modified by IL-15 genes, so that IL-2 injection is not carried out; untreated groups were injected with an equal volume of 1 XPBS. Tumor volume was measured twice weekly, tumor growth curves were drawn, and tumor inhibition was counted.
The test results are shown in FIG. 11: the treatment effect on an HPAF-II pancreatic cancer model shows that the peripheral blood-derived CAR-NK cells prepared based on the invention have a remarkably enhanced effect of inhibiting tumor growth compared with an NK cell control group which is not infected with the CAR lentivirus of the embodiment 1 of the invention; the tumor inhibition rate of the 4 multiplied by 10 6CAR- NK cell dosage group is 56.78 percent, and the tumor inhibition rate of the 1.6multiplied by 10 7CAR- NK cell dosage group is 80.97 percent.
Example 4CAR-NK cells were able to effectively kill immunosuppressive cells MSDCs within tumor microenvironment
In this example, the inventors examined the in vitro killing activity of the CAR-NK92 cells of the invention obtained in example 1 against MDSCs and the antitumor activity in tumor-bearing mouse models. In vivo, MDSCs were mixed with tumor cells and mice were treated for tumor-bearing, NK92 or CAR-NK92 cell feedback, and tumor burden was observed by in vivo imaging.
4.1 Induction of MDSCs by human peripheral blood PBMC
The inventors induced MDSCs with PBMCs from human peripheral blood.
The specific method comprises the following steps: human peripheral blood PBMC induced MDSC cells: after isolation of human peripheral blood PBMC, plates were plated and incubated with 100ng/mL IL-4 and 100ng/mL GM-CSF for 24h, followed by additional 25 μg/mL Poly (I: C) stimulation for 24h. The supernatant was discarded and adherent cells were collected by pancreatin digestion, i.e., induced MDSCs.
4.2 In vitro killing effect of CAR-NK92 cells on MDSCs
The inventors detected the killing efficiency of CAR-NK92 cells against MDSCs by LDH method.
The specific method comprises the following steps: incubating NK92 and CAR-NK92 cells with MDSCs for 4 hours respectively, and detecting killing efficiency by an LDH release method; and simultaneously adding NKG2D antibody (Ab blockade) into a killing system for blocking, and respectively setting controls of NK92 and CAR-NK92 cell groups. The ratio of effector cells to target cells was 10:1, 5:1 and 2.5:1.
The test results are shown in FIG. 12: the killing efficiency of the genetically modified CAR-NK92 cells of the invention on MICA/B positive MDSCs is obviously higher than that of NK92 cells when the effective target ratio is 10:1, 5:1 and 2.5:1. After NKG2D antibody is added into the killing system to block, the killing efficiency of NK92 and CAR-NK92 cells is obviously reduced.
4.3 Tumor inhibiting effect of CAR-NK92 cells on tumor-bearing mouse model of human liver cancer H7402 cells containing MDSCs
The specific method comprises the following steps:
The method for establishing the tumor-bearing mouse model of the human liver cancer H7402 cells containing MDSCs comprises the following steps: on day 0, 6-7 week old mice were selected, each mixed with 1x10 6 luciferase-labeled H7402 cells and 6x10 5 MDSCs for underarm subcutaneous tumor bearing. On day 3 after tumor bearing, tail vein reinfusion of NK92 or CAR-NK92 cells is carried out at a dose of 5x10 6 cells/dose, the reinfusion treatment is carried out once every 3 days for 3 times, and meanwhile, the IL-2 solution is injected intraperitoneally every 3 days at a dose of 5x10 4 IU/dose. On day 10, in vivo imaging observations were made.
The test results are shown in fig. 13: as can be seen from the results of live imaging, there was no significant difference in tumor burden in the NK92 cell group compared to the untreated group. The tumor burden of the CAR-NK92 cell group was significantly less than that of the untreated group and the NK92 cell group. This shows that the CAR-NK92 cells can effectively kill MDSCs in the tumor microenvironment, eliminate the inhibition of the MDSCs in the tumor on immune effector cells, and have stronger tumor inhibition effect than NK92 cells.
The test results show that the CAR-NK cells have strong killing effect on the MDSCs in tumors, can resist the immune suppression of the MDSCs on the CAR-NK or the CAR-T cells, exert stronger anti-tumor effect, and break through the bottleneck that immune cell therapy is subject to the immune suppression of the microenvironment of the solid tumor.
In the description of the present specification, a description referring to terms "one embodiment," "some embodiments," "examples," "specific examples," or "some examples," etc., means that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the present invention. In this specification, schematic representations of the above terms are not necessarily directed to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, the different embodiments or examples described in this specification and the features of the different embodiments or examples may be combined and combined by those skilled in the art without contradiction.
While embodiments of the present invention have been shown and described above, it will be understood that the above embodiments are illustrative and not to be construed as limiting the invention, and that variations, modifications, alternatives and variations may be made to the above embodiments by one of ordinary skill in the art within the scope of the invention.
Claims (16)
1. A chimeric antigen receptor comprising:
A first fragment, said first fragment being a NKG2D full-length sequence;
a second fragment, wherein the first fragment is a full-length sequence of DAP10, and the first fragment is connected with the second fragment;
An intracellular signaling domain, the N-terminus of the intracellular signaling domain being linked to the C-terminus of the first fragment, the intracellular signaling domain being an intracellular segment of a cd3ζ molecule; the amino acid sequence of the intracellular segment of the CD3 zeta molecule is shown as SEQ ID NO:3 is shown in the figure;
the amino acid sequence of the NKG2D full-length sequence is shown in SEQ ID NO:1 is shown in the specification;
The amino acid sequence of the full-length sequence of the DAP10 is shown as SEQ ID NO:2 is shown in the figure;
Further comprises: a first linker, the first fragment and the second fragment being linked by the first linker; the amino acid sequence of the first connector is shown as SEQ ID NO: shown as 8;
Further comprises: a second linker and a fusion protein, the N-terminus of the second fragment and the C-terminus of the fusion protein being linked by the second linker; the amino acid sequence of the second linker is shown in SEQ ID NO: shown as 8; the amino acid sequence of the fusion protein is shown as SEQ ID NO: shown at 13.
2. A nucleic acid molecule encoding the chimeric antigen receptor of claim 1.
3. The nucleic acid molecule of claim 2, comprising a first nucleic acid molecule, a second nucleic acid molecule, and a third nucleic acid molecule; the first nucleic acid molecule and the second nucleic acid molecule are linked by the third nucleic acid molecule;
The nucleotide sequence of the first nucleic acid molecule is shown as SEQ ID NO:10 is shown in the figure;
the nucleotide sequence of the second nucleic acid molecule is shown as SEQ ID NO: 14;
The nucleotide sequence of the third nucleic acid molecule is shown as SEQ ID NO: shown at 9.
4. The nucleic acid molecule of claim 2, wherein the nucleotide sequence of the nucleic acid molecule is set forth in SEQ ID NO: 15.
5. An expression vector carrying the nucleic acid molecule of any one of claims 2 to 4.
6. The expression vector of claim 5, wherein the expression vector is a non-pathogenic viral vector.
7. The expression vector of claim 6, wherein the non-pathogenic viral vector is optionally one of a retrovirus vector, a chronic virus vector and an adenovirus-associated virus vector.
8. The expression vector of claim 6, wherein the non-pathogenic viral vector is a lentiviral vector.
9. A transgenic immune cell comprising:
Expressing the chimeric antigen receptor of claim 1; or alternatively
Carrying the nucleic acid molecule of any one of claims 2 to 4 or the expression vector of any one of claims 5 to 8.
10. The transgenic immune cell of claim 9, wherein the transgenic immune cell is obtained by introducing the expression vector into an immune cell.
11. The transgenic immune cell of claim 10, wherein the immune cell is selected from at least one of T cells, NK cells, macrophages, and ipscs.
12. The transgenic immune cell of claim 11, wherein the T cell is selected from at least one of NKT cells, γδ T cells, and the NK cell is selected from at least one of peripheral blood NK cells, umbilical cord blood NK cells, iPSC-derived NK cells, NK-92 cells.
13. The transgenic immune cell of claim 10, wherein the immune cell is selected from the group consisting of NK cells.
14. A pharmaceutical composition comprising:
The chimeric antigen receptor of claim 1, the nucleic acid molecule of any one of claims 2 to 4, the expression vector of any one of claims 5 to 8, or the transgenic immune cell of any one of claims 9 to 13.
15. The pharmaceutical composition of claim 14, further comprising: pharmaceutically acceptable auxiliary materials.
16. Use of the chimeric antigen receptor of claim 1, the nucleic acid molecule of any one of claims 2 to 4, the expression vector of any one of claims 5 to 8, the transgenic immune cell of any one of claims 9 to 13, or the pharmaceutical composition of claim 14 or 15 in the preparation of a medicament for preventing or treating a tumor, the tumor being at least one of liver cancer, ovarian cancer, and pancreatic cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310687031.8A CN116836299B (en) | 2023-06-09 | 2023-06-09 | Chimeric antigen receptor and uses thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310687031.8A CN116836299B (en) | 2023-06-09 | 2023-06-09 | Chimeric antigen receptor and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116836299A CN116836299A (en) | 2023-10-03 |
CN116836299B true CN116836299B (en) | 2024-07-09 |
Family
ID=88171562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310687031.8A Active CN116836299B (en) | 2023-06-09 | 2023-06-09 | Chimeric antigen receptor and uses thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116836299B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117511977A (en) * | 2023-11-24 | 2024-02-06 | 上海恩凯细胞技术有限公司 | Novel immune cells for treating tumors and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109734813A (en) * | 2019-01-28 | 2019-05-10 | 广东昭泰体内生物医药科技有限公司 | A kind of Chimeric antigen receptor and its application |
CN110028589A (en) * | 2018-02-07 | 2019-07-19 | 阿思科力(苏州)生物科技有限公司 | Chimeric antigen receptor, the NKG2D CAR-NK cell for expressing the Chimeric antigen receptor and its preparation method and application |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102115236B1 (en) * | 2018-01-29 | 2020-05-27 | (주)에스엠티바이오 | Chimera antigen receptors for treating pancreatic cancer or biliary tract cancer |
CN110055224B (en) * | 2019-04-03 | 2023-06-30 | 深圳市体内生物医药科技有限公司 | Genetically modified immune cell and preparation method and application thereof |
CN110627909B (en) * | 2019-08-28 | 2021-03-30 | 中国人民解放军第二军医大学 | Chimeric antigen receptor for specifically activating NK cells and application thereof |
CN111484559B (en) * | 2020-03-03 | 2023-05-23 | 浙江启新生物技术有限公司 | Construction and application of third generation NKG2D chimeric antigen receptor T or NK cell |
-
2023
- 2023-06-09 CN CN202310687031.8A patent/CN116836299B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110028589A (en) * | 2018-02-07 | 2019-07-19 | 阿思科力(苏州)生物科技有限公司 | Chimeric antigen receptor, the NKG2D CAR-NK cell for expressing the Chimeric antigen receptor and its preparation method and application |
CN109734813A (en) * | 2019-01-28 | 2019-05-10 | 广东昭泰体内生物医药科技有限公司 | A kind of Chimeric antigen receptor and its application |
Also Published As
Publication number | Publication date |
---|---|
CN116836299A (en) | 2023-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108018299B (en) | Chimeric antigen receptor targeting BCMA and uses thereof | |
US20210196756A1 (en) | Anti-cd19 car-t cell | |
CN109320615B (en) | Chimeric antigen receptor targeting novel BCMA and uses thereof | |
CN113621582B (en) | Engineered immune cell for combined expression of CCR2b, and preparation and application thereof | |
CN111944054B (en) | anti-BCMA CAR and expression vector and application thereof | |
CN113755448B (en) | Engineered immune cells jointly expressing CCR2b and CD40L, and preparation and application thereof | |
CN115838439B (en) | Preparation method and application of chimeric transition receptor gene modified NK cells | |
CN116836299B (en) | Chimeric antigen receptor and uses thereof | |
CN110923255A (en) | Chimeric antigen receptor targeting BCMA and CD19 and uses thereof | |
WO2020248486A1 (en) | Method for preparing car-t that uses tcm as main effective ingredient and use thereof | |
CN106117367B (en) | HER-3 specific chimeric antigen receptor and application thereof | |
WO2024119686A9 (en) | Preparation method for and use of chimeric switch receptor gene modified nk cell | |
CN116041542A (en) | NK cell preparation method for reversing tumor microenvironment inhibitory signals and application | |
CN109517798B (en) | NK (natural killer) cell of chimeric CEA antigen receptor as well as preparation method and application of NK cell | |
CN111748043B (en) | Chimeric antigen receptor and application thereof | |
JP2022501067A (en) | Chimeric antigen receptors targeting BCMA and CD19, and their use | |
CN115552019A (en) | Viral vectors for the specific expression of therapeutic proteins in myeloid and microglia cells | |
CN116589584A (en) | Antibodies or fragments thereof targeting human Nectin4 protein and uses thereof | |
CN116254230A (en) | Method for preparing and amplifying universal humanized anti-CD 19CAR-NK cells and uses thereof | |
CN115819614A (en) | Preparation and application of chimeric antigen receptor immune cells based on IL34 | |
CN117304342B (en) | Chimeric antigen receptor and uses thereof | |
CN116925236B (en) | Chimeric transition receptors and uses thereof | |
WO2017117890A1 (en) | Il-12/cd107a fusion protein and preparation method and use thereof | |
CN113549157B (en) | Double-targeting chimeric antigen receptor and application thereof | |
CN117660500A (en) | Nucleic acid construct, vector, transgenic immune cell and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |